These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

370 related articles for article (PubMed ID: 27502552)

  • 1. Oral sildenafil as a treatment option for lymphatic malformations in PIK3CA-related tissue overgrowth syndromes.
    Horbach SE; Jolink F; van der Horst CM
    Dermatol Ther; 2016 Nov; 29(6):466-469. PubMed ID: 27502552
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Update on classification and diagnosis of vascular malformations.
    McCuaig CC
    Curr Opin Pediatr; 2017 Aug; 29(4):448-454. PubMed ID: 28654575
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lymphatic and other vascular malformative/overgrowth disorders are caused by somatic mutations in PIK3CA.
    Luks VL; Kamitaki N; Vivero MP; Uller W; Rab R; Bovée JV; Rialon KL; Guevara CJ; Alomari AI; Greene AK; Fishman SJ; Kozakewich HP; Maclellan RA; Mulliken JB; Rahbar R; Spencer SA; Trenor CC; Upton J; Zurakowski D; Perkins JA; Kirsh A; Bennett JT; Dobyns WB; Kurek KC; Warman ML; McCarroll SA; Murillo R
    J Pediatr; 2015 Apr; 166(4):1048-54.e1-5. PubMed ID: 25681199
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Klippel-Trenaunay syndrome belongs to the PIK3CA-related overgrowth spectrum (PROS).
    Vahidnezhad H; Youssefian L; Uitto J
    Exp Dermatol; 2016 Jan; 25(1):17-9. PubMed ID: 26268729
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CLOVES syndrome: review of a PIK3CA-related overgrowth spectrum (PROS).
    Martinez-Lopez A; Blasco-Morente G; Perez-Lopez I; Herrera-Garcia JD; Luque-Valenzuela M; Sanchez-Cano D; Lopez-Gutierrez JC; Ruiz-Villaverde R; Tercedor-Sanchez J
    Clin Genet; 2017 Jan; 91(1):14-21. PubMed ID: 27426476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-hotspot PIK3CA mutations are more frequent in CLOVES than in common or combined lymphatic malformations.
    Brouillard P; Schlögel MJ; Homayun Sepehr N; Helaers R; Queisser A; Fastré E; Boutry S; Schmitz S; Clapuyt P; Hammer F; Dompmartin A; Weitz-Tuoretmaa A; Laranne J; Pasquesoone L; Vilain C; Boon LM; Vikkula M
    Orphanet J Rare Dis; 2021 Jun; 16(1):267. PubMed ID: 34112235
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vascular malformations syndromes: an update.
    Martinez-Lopez A; Salvador-Rodriguez L; Montero-Vilchez T; Molina-Leyva A; Tercedor-Sanchez J; Arias-Santiago S
    Curr Opin Pediatr; 2019 Dec; 31(6):747-753. PubMed ID: 31693582
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [PIK3CA-related overgrowth syndrome (PROS)].
    Venot Q; Canaud G
    Nephrol Ther; 2017 Apr; 13 Suppl 1():S155-S156. PubMed ID: 28577738
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined capillary-venous-lymphatic malformations without overgrowth in patients with Klippel-Trénaunay syndrome.
    Brandigi E; Torino G; Messina M; Molinaro F; Mazzei O; Matucci T; López Gutiérrez JC
    J Vasc Surg Venous Lymphat Disord; 2018 Mar; 6(2):230-236. PubMed ID: 29233587
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An open-label study to evaluate sildenafil for the treatment of lymphatic malformations.
    Danial C; Tichy AL; Tariq U; Swetman GL; Khuu P; Leung TH; Benjamin L; Teng J; Vasanawala SS; Lane AT
    J Am Acad Dermatol; 2014 Jun; 70(6):1050-7. PubMed ID: 24656411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Somatic PIK3CA mutations in seven patients with PIK3CA-related overgrowth spectrum.
    Yeung KS; Ip JJ; Chow CP; Kuong EY; Tam PK; Chan GC; Chung BH
    Am J Med Genet A; 2017 Apr; 173(4):978-984. PubMed ID: 28328134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cerebrofacial vascular metameric syndrome is caused by somatic pathogenic variants in
    Sheppard SE; Sanders VR; Srinivasan A; Finn LS; Adams D; Elton A; Amlie-Lefond C; Nelson Z; Dmyterko V; Jensen D; Zenner K; Perkins J; Bennett JT
    Cold Spring Harb Mol Case Stud; 2021 Dec; 7(6):. PubMed ID: 34887309
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [New nosological and therapeutic perspectives in syndromic vascular malformations with a vein-lymphatic component].
    Henneton P; Mestre S; Nou M; Quere I
    Rev Med Interne; 2018 Oct; 39(10):800-804. PubMed ID: 29627129
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical delineation and natural history of the PIK3CA-related overgrowth spectrum.
    Keppler-Noreuil KM; Sapp JC; Lindhurst MJ; Parker VE; Blumhorst C; Darling T; Tosi LL; Huson SM; Whitehouse RW; Jakkula E; Grant I; Balasubramanian M; Chandler KE; Fraser JL; Gucev Z; Crow YJ; Brennan LM; Clark R; Sellars EA; Pena LD; Krishnamurty V; Shuen A; Braverman N; Cunningham ML; Sutton VR; Tasic V; Graham JM; Geer J; Henderson A; Semple RK; Biesecker LG
    Am J Med Genet A; 2014 Jul; 164A(7):1713-33. PubMed ID: 24782230
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overgrowth syndromes with vascular malformations.
    Hagen SL; Hook KP
    Semin Cutan Med Surg; 2016 Sep; 35(3):161-9. PubMed ID: 27607325
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic basis for vascular anomalies.
    Kirkorian AY; Grossberg AL; Püttgen KB
    Semin Cutan Med Surg; 2016 Sep; 35(3):128-36. PubMed ID: 27607321
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Causal somatic mutations in urine DNA from persons with the CLOVES subgroup of the PIK3CA-related overgrowth spectrum.
    Michel ME; Konczyk DJ; Yeung KS; Murillo R; Vivero MP; Hall AM; Zurakowski D; Adams D; Gupta A; Huang AY; Chung BHY; Warman ML
    Clin Genet; 2018 May; 93(5):1075-1080. PubMed ID: 29231959
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diffuse capillary malformation with overgrowth contains somatic PIK3CA variants.
    Goss JA; Konczyk DJ; Smits P; Sudduth CL; Bischoff J; Liang MG; Greene AK
    Clin Genet; 2020 May; 97(5):736-740. PubMed ID: 31909475
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prenatal diagnosis of CLOVES syndrome confirmed by detection of a mosaic PIK3CA mutation in cultured amniocytes.
    Emrick LT; Murphy L; Shamshirsaz AA; Ruano R; Cassady CI; Liu L; Chang F; Sutton VR; Li M; Van den Veyver IB
    Am J Med Genet A; 2014 Oct; 164A(10):2633-7. PubMed ID: 25044986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PI3K/mTOR inhibition promotes the regression of experimental vascular malformations driven by PIK3CA-activating mutations.
    di Blasio L; Puliafito A; Gagliardi PA; Comunanza V; Somale D; Chiaverina G; Bussolino F; Primo L
    Cell Death Dis; 2018 Jan; 9(2):45. PubMed ID: 29352118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.